Picture of the day: digest of the main news from July 11, 2025
Main
#1 The Russian Ministry of Health has significantly revised the list of criteria for assessing the work of medical organizations with the assigned population, adding or introducing 16 target indicators. Now, for example, a clinic will not receive a bonus from the compulsory medical insurance budget if it has not conducted the required number of examinations of the adult population who have not been seen for a medical examination for more than two years. The requirements for identifying malignant neoplasms and for the medical observation of patients with circulatory diseases are also being tightened. In addition, the results of medical care quality assessments will be assessed for the first time.
#2 The Ministry of Health presented a draft order providing for the postponement of the deadline for the complete refusal of the paper version of medical books for workers in a number of industries, generated after passing medical examinations for admission to work. Now it is proposed to move the date of entry into force of the regulation to 2026. The regulator planned that some workers will be able to refuse a physical medical book in favor of an electronic one by September 1, 2023, but in the end, the implementation of the initiative was repeatedly postponed, most recently until September 1, 2025.
Exclusively
According to industry analysts, the generic segment has become the main driver of growth in the Russian pharmaceutical industry. In 2024, the sales volume of generic drugs exceeded 1.5 trillion rubles, which in the overall market structure corresponds to a share of 61.7%. This figure has added 12.4% year on year, as specified by DSM Group, confidently predicting a continuation of the upward trend to the 2.8 trillion ruble mark over the next five years. Moreover, the main role in the expanding generic field will be played by domestic pharmaceutical manufacturers, which have made a noticeable scientific and technological breakthrough in recent years. Experts and market participants see several more prerequisites for maintaining the positive dynamics for the sale of generic drugs, including increased patient confidence in domestic drugs, support and increased control by regulators, and a reduction in the presence of foreign capital in the domestic pharmaceutical market. Read more in the review .
Pharmaceutical business
The company "Avexima" has begun construction of a pharmaceutical production and logistics complex with an area of over 170 thousand square meters. The facility, announced in 2017, will be built on the territory of the industrial park "Esipovo" in the Moscow region. The investment volume is estimated at 6.5 billion rubles. The cluster will include a laboratory for the development of new drugs, a plant where the company intends to carry out the entire cycle of drug production, and a number of other premises. The first stage of the complex will be commissioned in 2027.
Infrastructure
The Moscow Department of Competition Policy is looking for a contractor to carry out major repairs to the building of City Polyclinic No. 219, taking into account the placement of a Women's Health Center there. It is planned that the center on Yana Rainisa Boulevard will begin operating in 2027. 2 billion rubles will be allocated from the capital's budget for these purposes. From 2024 to 2025, the city authorities have announced at least ten purchases for major repairs in various medical institutions of the city with the aim of opening women's health centers for a total of almost 9.5 billion rubles.
Government support
A group of State Duma deputies and Federation Council senators submitted a bill to the lower house of parliament that proposes expanding the list of activities of socially oriented NPOs deserving support from state and municipal authorities. Thus, the list may be expanded to include NPOs in the area of rehabilitation and psychological assistance to combat veterans, their family members, and the families of the deceased. The amendments are being made to Article 31.1 No. 7-FZ "On Non-Commercial Organizations" of January 12, 1996.
International agenda
The Supreme Court of the US state of Delaware has rejected expert opinions used in 75,000 lawsuits against GSK, Pfizer, Sanofi and Boehringer Ingelheim over the possible development of cancer in patients associated with taking the heartburn drug Zantac (ranitidine). The court sided with the pharmaceutical companies and excluded the testimony of ten doctors and scientists from the court materials. Eight of them claimed that ranitidine provokes about ten types of cancer. Since 2018, various organizations began reporting on the carcinogenic properties of ranitidine, which was followed by the withdrawal of the drug from circulation in various countries and lawsuits against the companies. In total, more than 80,000 lawsuits have been filed in the US against GSK, 70,000 against Sanofi and 10,000 against Pfizer.
Other news:
Google Releases Open AI Model for Healthcare Developers
Moderna Receives Full FDA Approval for COVID-19 Vaccine for At-Risk Children 6 Months and Older
vademec
